Advertisement

Hypnotic Discontinuation in Chronic Insomnia

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ohayon M.M.
        Epidemiology of insomnia: what we know and what we still need to learn.
        Sleep Med Rev. 2002; 6: 97-111
        • Calhoun S.L.
        • Fernandez-Mendoza J.
        • Vgontzas A.N.
        • et al.
        Prevalence of insomnia symptoms in a general population sample of young children and preadoles-cents: gender effects.
        Sleep Med. 2014; 15: 91-95
        • Chung K.F.
        • Yeung W.F.
        • Ho F.Y.
        • et al.
        Cross-cultural and comparative epidemiology of insomnia: the Diagnostic and Statistical Manual (DSM), Interna tional Classification of Diseases (ICD) and Interna-tional Classification of sleep disorders (ICSD).
        Sleep Med. 2015; 16: 477-482
        • Kronholm E.
        • Partonen T.
        • Härmä M.
        • et al.
        Prevalence of insomnia-related symptoms continues to increase in the Finnish working-age population.
        J Sleep Res. 2016; 25: 454-457
        • Seow L.S.
        • Subramaniam M.
        • Abdin E.
        • et al.
        Sleep disturbance among people with major depressive disorders (MDD) in Singapore.
        J Ment Health. 2016; 25: 492-499
        • Kim K.W.
        • Kang S.H.
        • Yoon I.Y.
        • et al.
        Prevalence and clinical characteristics of insomnia and its subtypes in the Korean elderly.
        Arch Gerontol Geriatr. 2017; 68: 68-75
        • Walsh J.K.
        Pharmacologic management of insomnia.
        J Clin Psychiatry. 2004; 65: 41-45
        • Owens J.A.
        • Rosen C.L.
        • Mindell J.A.
        Medication use in the treatment of pediatric insomnia: results of a sur vey of community-based pediatricians.
        Pediatrics. 2003; 111: e628-e635
        • Nguyen M.
        • Tharani S.
        • Rahmani M.
        • et al.
        A review of the use of Clonidine as a sleep aid in the child and adolescent population.
        Clin Pediatr (Phila). 2014; 53: 211-216
        • Schutte-Rodin S.
        • Broch L.
        • Buysse D.
        • et al.
        Clinical guideline for the evaluation and management of chronic insomnia in adults.
        J Clin Sleep Med. 2008; 4: 487-504
        • Ostini R.
        • Jackson C.
        • Hegney D.
        • et al.
        How is medi cation prescribing ceased? A systematic review.
        Med Care. 2011; 49: 24-36
        • Kales A.
        • Scharf M.B.
        • Kales J.D.
        Rebound insomnia: a new clinical syndrome.
        Science. 1978; 201: 1039-1041
        • Roehrs T.
        Rebound insomnia: its determinants and significance.
        Am J Med. 1990; 88: 39S-42S
        • Soldatos C.R.
        • Dikeos D.G.
        • Whitehead A.
        Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies.
        Int Clin Psychopharmacol. 1999; 14: 287-303
        • Staner L.
        • Kerkhofs M.
        • Detroux D.
        • et al.
        Acute, sub-chronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression.
        Sleep. 1995; 18: 470-477
        • Montgomery I.
        • Oswald I.
        • Morgan K.
        • et al.
        Trazodone enhances sleep in subjective quality but not in objective duration.
        Br J Clin Pharmacol. 1983; 16: 139-144
        • Monti J.M.
        • Attali P.
        • Monti D.
        • et al.
        Zolpidem and rebound insomnia-a double-blind, controlled poly-somnographic study in chronic insomniac patients.
        Pharmacopsychiatry. 1994; 27: 166-175
        • Silvestri R.
        • Ferrillo F.
        • Murri L.
        • et al.
        Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam.
        Hum Psychopharmacol. 1996; 11: 225-233
        • Voshaar R.C.
        • van Balkom A.J.
        • Zitman F.G.
        Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study.
        Eur Neuropsychophar-macol. 2004; 14: 301-306
        • Rickels K.
        • Schweizer E.
        • Case W.G.
        • et al.
        Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation.
        Arch Gen Psychiatry. 1990; 47: 899-907
        • Hopkins D.R.
        • Sethi K.B.
        • Mucklow J.C.
        Benzodiazepine withdrawal in general practice.
        J R Coll Gen Pract. 1982; 32: 758-762
        • Murphy S.M.
        • Tyrer P.
        A double-blind comparison of the effects of gradual withdrawal of lorazepam, diaz epam and bromazepam in benzodiazepine depen dence.
        Br J Psychiatry. 1991; 158: 511-516
        • Voshaar R.C.
        • Gorgels W.J.
        • Mol A.J.
        • et al.
        Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial.
        Br J Psychia Try. 2003; 182: 498-504
        • Gorgels W.J.
        • Oude Voshaar R.C.
        • Mol A.J.
        • et al.
        Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a pro spective controlled intervention study.
        Drug Alcohol Depend. 2005; 78: 49-56
        • Morin C.M.
        • Bastien C.H.
        • Guay B.
        • et al.
        Randomized clinical trial of supervised tapering and cognitive-behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia.
        Am J Psychiatry. 2004; 161: 332-342
        • Lopez-Peig C.
        • Mundet X.
        • Casabella B.
        • et al.
        Anal-ysis of benzodiazepine withdrawal program managed by primary care nurses in Spain.
        BMC Res Notes. 2012; 5: 684
        • Vicens C.
        • Sempere E.
        • Bejarano F.
        • et al.
        Efficacy of two interventions on the discontinuation of benzodi azepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care.
        Br J Gen Pract. 2016; 66: e85-e91
        • Drake J.
        Temazepam ‘Planpak’: a multicentre gen eral practice trial in planned benzodiazepine hyp notic withdrawal.
        Curr Med Res Opin. 1991; 12: 390-393
        • Lemoine P.
        • Allain H.
        • Janus C.
        • et al.
        Gradual with-drawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months.
        Eur Psychiatry. 1995; 10: 161s-165s
        • Raju B.
        • Meagher D.
        Patient-controlled benzodiaze-pine dose reduction in a community mental health service.
        Ir J Psychol Med. 2005; 22: 42-45
        • ClinicalTrials. gov
        The role of tapering pace and selected traits on hypnotic discontinuation.
        National Library of Medicine (US), Bethesda (MD)2016 (Identifier NCT02831894, Available at:) (Accessed August 17, 2017)
        • Lader M.
        • Tylee A.
        • Donoghue J.
        Withdrawing benzo-diazepines in primary care.
        CNS Drugs. 2009; 23: 19-34
        • Denis C.
        • Fatséas M.
        • Lavie E.
        • et al.
        Pharmacological in-terventions for benzodiazepine mono-dependence management in outpatient settings.
        Cochrane Data-base Syst Rev. 2006; 3: CD005194
        • Bashir K.
        • King M.
        • Ashworth M.
        Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines.
        Br J Gen Pract. 1994; 44: 408-412
        • Cormack M.A.
        • Sweeney K.G.
        • Hughes-Jones H.
        • et al.
        Evaluation of an easy, cost-effective strategy for cut ting benzodiazepine use in general practice.
        Br J Gen Pract. 1994; 44: 5-8
        • Stewart R.
        • Niessen W.J.
        • Broer J.
        • et al.
        General Prac titioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application.
        J Clin Epidemiol. 2007; 60: 1076-1084
        • Tannenbaum C.
        • Martin P.
        • Tamblyn R.
        • et al.
        Reduc tion of inappropriate benzodiazepine prescriptions among older adults through direct patient educa tion: the EMPOWER cluster randomized trial.
        JAMA Intern Med. 2014; 174: 890-898
        • Morgenthaler T.
        • Kramer M.
        • Alessi C.
        • et al.
        Amer ican Academy of Sleep Medicine. Practice param eters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report.
        Sleep. 2006; 29: 1415-1419
        • Giblin M.J.
        • Clift A.D.
        Sleep without drugs.
        J R Coll Gen Pract. 1983; 33: 628-633
        • Lichstein K.L.
        • Johnson R.S.
        Relaxation for insomnia and hypnotic medication use in older women.
        Psy-chol Aging. 1993; 8: 103-111
        • Lichstein K.L.
        • Peterson B.A.
        • Riedel B.W.
        • et al.
        Relaxa tion to assist sleep medication withdrawal.
        Behav Modif. 1999; 23: 379-402
        • Bootzin R.R.
        Stimulus control treatment for insomnia.
        Am Psychol Ass Proc. 1972; 7: 395-396
        • Baillargeon L.
        • Demers M.
        • Ladouceur R.
        Stimulus-control: nonpharmacologic treatment for insomnia.
        Can Fam Physician. 1998; 44: 73-79
        • Riedel B.
        • Lichstein K.
        • Peterson B.A.
        • et al.
        A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs.
        Behav Modif. 1998; 22: 3-28
        • Morin C.M.
        • Bootzin R.R.
        • Buysse D.J.
        • et al.
        Psycholog-ical and behavioral treatment of insomnia: update of the recent evidence (1998-2004).
        Sleep. 2006; 29: 1398-1414
        • Taylor D.J.
        • Schmidt-Nowara W.
        • Jessop C.A.
        • et al.
        Sleep restriction therapy and hypnotic withdrawal versus sleep hygiene education in hypnotic using patients with insomnia.
        J Clin Sleep Med. 2010; 6: 169-175
        • Morin C.M.
        • Colecchi C.A.
        • Ling W.D.
        • et al.
        Cognitive behavior therapy to facilitate benzodiazepine discontinuation among hypnotic-dependent patients with insomnia.
        Behav Ther. 1995; 26: 733-745
        • Baillargeon L.
        • Landreville P.
        • Verreault R.
        • et al.
        Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a random-ized trial.
        CMAJ. 2003; 169: 1015-1020
        • Vorma H.
        • Naukkarinen H.
        • Sarna S.
        • et al.
        Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches.
        Addiction. 2002; 97: 851-859
        • O’Connor K.
        • Marchand A.
        • Brousseau L.
        • et al.
        Cogni-tive-behavioural, pharmacological and psychosocial predictors of outcome during tapered discontinua tion of benzodiazepine.
        Clin Psychol Psychother. 2008; 15: 1-14
        • Zavesicka L.
        • Brunovsky M.
        • Matousek M.
        • et al.
        Discontinuation of hypnotics during cognitive behavioural therapy for insomnia.
        BMC psychiatry. 2008; 8: 80
        • Belleville G.
        • Guay C.
        • Guay B.
        • et al.
        Hypnotic taper with or without self-help of insomnia: a randomized clinical trial.
        J Consult Clin Psychol. 2007; 75: 325-335
        • Morgan K.
        • Dixon S.
        • Mathers N.
        • et al.
        Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial.
        Br J Gen Pract. 2003; 53: 923-928
        • Lichstein K.L.
        • Nau S.D.
        • Wilson N.M.
        • et al.
        Psycholog ical treatment of hypnotic-dependent insomnia in a primarily older adult sample.
        Behav Res Ther. 2013; 51: 787-796
        • Bélanger L.
        • Morin C.M.
        • Bastien C.
        • et al.
        Self-efficacy and compliance with benzodiazepine taper in older adults with chronic insomnia.
        Health Psychol. 2005; 24: 281-287
        • Yang C.M.
        • Tseng C.H.
        • Lai Y.S.
        • et al.
        Self-efficacy enhancement can facilitate hypnotic tapering in pa tients with primary insomnia.
        Sleep Biol Rhythms. 2015; 13: 242-251
        • Romach M.K.
        • Kaplan H.L.
        • Busto U.E.
        • et al.
        A controlled trial of ondansetron, a 5-HT3 antago-nist, in benzodiazepine discontinuation.
        J Clin Psy-chopharmacol. 1998; 18: 121-131
        • Rickels K.
        • DeMartinis N.
        • García-España F.
        • et al.
        Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontin- uing long-term benzodiazepine therapy.
        Am J Psy- Chiatry. 2000; 157: 1973-1979
        • Rynn M.
        • García-España F.
        • Greenblatt D.J.
        • et al.
        Imip ramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
        J Clin Psychopharmacol. 2003; 23: 505-508
        • Ashton C.H.
        • Rawlins M.D.
        • Tyrer S.P.
        A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users.
        Br J Psychiatry. 1990; 157: 232-238
        • Nakao M.
        • Takeuchi T.
        • Nomura K.
        • et al.
        Clinical appli cation of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
        Psychiatry Clin Neurosci. 2006; 60: 605-610
        • Schweizer E.
        • Rickels K.
        • Case W.G.
        • et al.
        Carbamaz- epine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.
        Arch Gen Psychiatry. 1991; 48: 448-452
        • Bobes J.
        • Rubio G.
        • Terán A.
        • et al.
        Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice.
        Eur Psychiatry. 2012; 27: 301-307
        • Schweizer E.
        • Case W.G.
        • Garcia-Espana F.
        • et al.
        Pro gesterone co-administration in patients discontinu ing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome.
        Psychophar- macology (Berl). 1995; 117: 424-429
        • Gilhooly T.C.
        • Webster M.G.
        • Poole N.W.
        • et al.
        What happens when doctors stop prescribing temaze- pam? Use of alternative therapies.
        Br J Gen Pract. 1998; 48: 1601-1602
        • Hallström C.
        • Crouch G.
        • Robson M.
        • et al.
        The treat ment of tranquilizer dependence by propranolol.
        Postgrad Med J. 1988; 64: 40-44
        • Pat-Horenczyk R.
        • Hacohen D.
        • Herer P.
        • et al.
        The ef fects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics.
        Psycho- Pharmacol (Berl). 1998; 140: 450-457
        • Shapiro C.M.
        • MacFarlane J.G.
        • MacLean A.W.
        Allevi ating sleep-related discontinuance symptoms associated with benzodiazepine withdrawal: a new approach.
        J Psychosom Res. 1993; 37: 55-57
        • Shapiro C.
        • Sherman D.
        • Peck D.
        Withdrawal from benzodiazepines by initially switching to zopiclone.
        Eur Psychiatry. 1995; 10 (145s-51s)
        • Lemoine P.
        • Ohayon M.M.
        Is hypnotic withdrawal facil- itated by the transitory use of a substitute drug?.
        Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21: 111-124
        • Kunz D.
        • Bineau S.
        • Maman K.
        • et al.
        Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription data base.
        Expert Opin Pharmacother. 2012; 13: 9-16
        • Garfinkel D.
        • Zisapel N.
        • Wainstein J.
        • et al.
        Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach.
        Arch Intern Med. 1999; 159: 2456-2460
        • Garzón C.
        • Guerrero J.M.
        • Aramburu O.
        • et al.
        Effect of melatonin administration on sleep, behavioral disor ders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo- controlled study.
        Aging Clin Exp Res. 2009; 21: 38-42
        • Cardinali D.P.
        • Gvozdenovich E.
        • Kaplan M.R.
        • et al.
        A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiaze pine use in the elderly.
        Neuroendocrinol Lett. 2002; 23: 55-60
        • Peles E.
        • Hetzroni T.
        • Bar-Hamburger R.
        • et al.
        Mela tonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial.
        Addiction. 2007; 102: 1947-1953
        • Vissers F.H.
        • Knipschild P.G.
        • Crebolder H.F.
        Is mela tonin helpful in stopping the long-term use of hyp notics? A discontinuation trial.
        Pharm World Sci. 2007; 29: 641-646
        • Lähteenmäki R.
        • Puustinen J.
        • Vahlberg T.
        • et al.
        Mela tonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind pla- cebo-controlled trial.
        Br J Clin Pharmacol. 2014; 77: 975-985
        • Baandrup L.
        • Lindschou J.
        • Winkel P.
        • et al.
        Prolonged- release melatonin versus placebo for benzodiaze pine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo- controlled, blinded trial.
        World J Biol Psychiatry. 2016; 17: 514-524
        • Wright A.
        • Diebold J.
        • Otal J.
        • et al.
        The effect of melatonin on benzodiazepine discontinuation and sleep quality in adults attempting to dis- continue benzodiazepines: a systematic review and meta-analysis.
        Drugs Aging. 2015; 32: 1009-1018
        • Fernández-San-Martín M.I.
        • Masa-Font R.
        • Palacios- Soler L.
        • et al.
        Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials.
        Sleep Med. 2010; 11: 505-511
        • Poyares D.R.
        • Guilleminault C.
        • Ohayon M.M.
        • et al.
        Can valerian improve the sleep of insomniacs af- ter benzodiazepine withdrawal?.
        Prog Neuropsy- Chopharmacol Biol Psychiatry. 2002; 26: 539-545